Clinical trial · Observational
Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT
A Study of Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Acute myeloid leukemia (AML) is a genetically heterogeneous disease and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment option for AML except for AML-M3. Relapse remains the major cause of treatment failure after allo-HSCT. Molecular residual disease has been shown to be a strong risk factor for relapse after HSCT. In this study, the investigators will detect mutations before/after allo-HSCT by using next-generation sequencing (NGS) technique to measure residual disease and evaluate the prognostic impact of molecular residual disease in a cohort of AML participants receiving allo-HSCT.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- 1-year relapse rate after allo-HSCT
- timeFrame
- 1 year after allo-HSCT
- description
- 1-year relapse rate after allo-HSCT
Secondary outcomes (2)
- measure
- 1-year recurrence-free survival (RFS)
- timeFrame
- 1 year after allo-HSCT
- description
- 1-year recurrence-free survival for AML participants
- measure
- 1-year overall survival (OS)
- timeFrame
- 1 year after allo-HSCT
- description
- 1-year overall survival (OS) for AML participants
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years or old; * Clinical diagnosis of acute myeloid leukemia (AML); * Availabe records of MICM and NGS results at diagnosis; * Be going to receive allo-HSCT. Exclusion Criteria: * Active malignancy; * Pregnant or breast feeding women.
References
Publications (25)
- BACKGROUNDDohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015 Sep 17;373(12):1136-52. doi: 10.1056/NEJMra1406184. No abstract available. PMID 26376137
- BACKGROUNDSchmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, Stadler M, Kuball J, Cornelissen J, Vorlicek J, Socie G, Falda M, Vindelov L, Ljungman P, Jackson G, Kroger N, Rank A, Polge E, Rocha V, Mohty M; Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012 Feb 9;119(6):1599-606. doi: 10.1182/blood-2011-08-375840. Epub 2011 Dec 13. PMID 22167752
- BACKGROUNDCorbacioglu A, Scholl C, Schlenk RF, Eiwen K, Du J, Bullinger L, Frohling S, Reimer P, Rummel M, Derigs HG, Nachbaur D, Krauter J, Ganser A, Dohner H, Dohner K. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol. 2010 Aug 10;28(23):3724-9. doi: 10.1200/JCO.2010.28.6468. Epub 2010 Jul 12. PMID 20625124
- BACKGROUNDYin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012 Oct 4;120(14):2826-35. doi: 10.1182/blood-2012-06-435669. Epub 2012 Aug 8. PMID 22875911
- BACKGROUNDGorello P, Cazzaniga G, Alberti F, Dell'Oro MG, Gottardi E, Specchia G, Roti G, Rosati R, Martelli MF, Diverio D, Lo Coco F, Biondi A, Saglio G, Mecucci C, Falini B. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia. 2006 Jun;20(6):1103-8. doi: 10.1038/sj.leu.2404149. PMID 16541144
- BACKGROUNDSchnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood. 2009 Sep 10;114(11):2220-31. doi: 10.1182/blood-2009-03-213389. Epub 2009 Jul 8.